These results strongly suggest that the Nrf2/HO-1/bilirubin axis may play a crucial role in the development of cholestatic liver injury, and that the intervention of Nrf2/HO-1 may be a potential therapeutic target for the treatment of cholestatic liver disease. The gene discussed is NFE2L2; the disease is Cholestatic liver disease.